Note 2 - Restructuring, Impairment and Other Charges and Credits	3 Months Ended
Mar. 31, 2021
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	2. Restructuring, Impairment and Other Charges and Credits *2021* There was no material restructuring, impairment and other charges and credits activity for the first quarter of 2021. *2020* During the three months ended March 31, 2020 we recorded $225 million in severance and costs to realign capacity of certain facilities in our Display Technologies segment in the Asia regions. Severance charges of $77 million were primarily related to a reduction in force program implemented, and substantially paid, during the quarter to facilitate realignment of capacity for these facilities. Charges of $148 million to realign capacity included accelerated depreciation and other related on-going exit costs. Total restructuring, impairment and other charges and credits were reflected on the consolidated statements of income (loss) as cost of sales of $161 million, selling, general and administrative expenses of $48 million, research development and engineering expenses of $13 million and other charges of $3 million.

Note 2 - Restructuring, Impairment and Other Charges and Credits

3 Months Ended

Mar. 31, 2021

Restructuring and Related Activities Disclosure [Text Block]

2. Restructuring, Impairment and Other Charges and Credits

2021

There was no material restructuring, impairment and other charges and credits activity for the first quarter of 2021.

2020

During the three months ended March 31, 2020 we recorded $225 million in severance and costs to realign capacity of certain facilities in our Display Technologies segment in the Asia regions. Severance charges of $77 million were primarily related to a reduction in force program implemented, and substantially paid, during the quarter to facilitate realignment of capacity for these facilities. Charges of $148 million to realign capacity included accelerated depreciation and other related on-going exit costs.

Total restructuring, impairment and other charges and credits were reflected on the consolidated statements of income (loss) as cost of sales of $161 million, selling, general and administrative expenses of $48 million, research development and engineering expenses of $13 million and other charges of $3 million.